Prospective Safety Study of Sintilimab Combined With XELOX Plus Bevacizumab for Preoperative Neoadjuvant Therapy of CRLM Patients With pMMR/MSS Status
Latest Information Update: 11 Jan 2024
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Sintilimab (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions
- 06 Jan 2024 Planned End Date changed from 30 Sep 2023 to 30 Oct 2024.
- 02 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Sep 2023.
- 02 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Sep 2023.